Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07386847 · ClinicalTrials.gov registry record
A Real-world Study of the First Treatment and Outcomes of Patients With Advanced or Metastatic Bladder Cancer
A clinical trial, sponsored by Pfizer.
- Completed
- Registry status
- 1
- Enrollment target
NCT07386847: Completed study, sponsored by Pfizer.
NCT07386847 is a clinical trial that has completed, run by Pfizer. The registered enrollment target is 1 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07386847 has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 1 participants
- Enrollment target
Study Summary
Bladder cancer (urothelial carcinoma) is a disease where cells in the bladder grow out of control. The bladder is an organ in the lower part of the body that stores urine. When someone has bladder cancer, abnormal cells form in the bladder and can spread to other parts of the body if not treated. Bladder cancer that has spread outside the bladder is called advanced or metastatic bladder cancer. The purpose of this study is to examine how long it takes for adults with advanced or metastatic bladder cancer to experience worsening of their disease following their first treatment . The researchers will also describe which medicines these patients use as their first treatment for the disease. This is a real-world study, not a clinical study. This means that researchers will look at what happens when patients receive the treatments prescribed by their own doctor as part of their usual healthcare treatment. In this study, researchers will use information from cancer clinics (Flatiron Health electronic health records). The study will include patients' information from the database who: * Were identified to have advanced or metastatic bladder cancer. * Started their first treatment after 01 Apr 2023. * Were 18 years of age or older when they were diagnosed with advanced disease.
Primary Outcome
Time from initiation of first line treatment for la/mUC to the earliest of disease progression or death, based on real-world data sources.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2026-02-12 |
| Est. Completion | 2026-03-30 |
What the finished NCT07386847 record still lists
NCT07386847 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 1 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT07386847 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07386847 about?
NCT07386847 is a clinical study titled "A Real-world Study of the First Treatment and Outcomes of Patients With Advanced or Metastatic Bladder Cancer". Bladder cancer (urothelial carcinoma) is a disease where cells in the bladder grow out of control. The bladder is an organ in the lower part of the body that stores urine. When someone has bladder cancer, abnormal cells form in the bladder and can spread to other parts of the body if not treated. Bl...
What is the current status of trial NCT07386847?
This trial is currently completed. The enrollment target is 1 participants. The study started on 2026-02-12. Estimated completion is 2026-03-30.
Who is sponsoring clinical trial NCT07386847?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI